Fri, Jul 23 | Online Event

Washington DC ArchAngels: Peer Review & Company Discussion

Brian Frenzel, CEO Tosk, Inc.
Registration is Closed
Washington DC ArchAngels: Peer Review & Company Discussion

Time & Location

Jul 23, 2:00 PM – 3:00 PM EDT
Online Event

About the Event

Washington DC ArchAngels RSVP Requested - Invitation Only (REGISTRATION IS REQUIRED) 

Click here to RSVP


Company Description Tosk Inc. provides new drugs that prevent undesirable side effects of widely-used cancer therapies and to block proteins produced by cancer genes that drive tumor growth. Using innovative Drosophila fly-based drug discovery methods, the company has initially identified two compounds (TK-90 and TK-39) that prevent adverse effects of cancer treatment, with important patient benefits such as avoiding decisions to terminate therapy due to severe side effects. Both products address dose limiting and potentially fatal adverse side effects including mucositis, cardiotoxicity, and nephrotoxicity. Mucositis is a significant side effect of leading cancer treatments such as methotrexate and radiation, therapies often used for breast, colon, head and neck, pancreatic cancers and leukemia.  Currently, the TK-90 compound has completed “proof of concept” in FDA Phase 2a clinical studies in head and neck cancer patients and also has applications outside of cancer including Covid 19. TK-39 has completed preclinical efficacy testing. Management team strengths include extensive experience in entrepreneurial enterprises (co-founders of a diagnostic and 3 therapeutic companies, and several other early-stage biotechnology companies) and drug research and development (Roche, Affymax, Bell Labs, Chemocentryx and Amunix). The company's primary business development strategy is focused on its discovery platform and identifying proprietary, small molecule drugs and moving drug development through proof of concept in human clinical studies, and followed by seeking partnerships with larger pharmaceutical companies. Based on current progress in its initial drug discovery and development, the company expects to achieve a partnered Phase 3 drug and two Phase 2 drugs in the pipeline within 18 months.

. About the Company:  SLIDE PRESENTATION Meet the Entrepreneur:  VIDEO PRESENTATION


Session Details:

Zoom Link:

Meeting ID: 967 2812 9644

Passcode: 253540

Audio only - phone dial in numbers:

➡ 646-876 9923 US (New York) ➡ 301-715-8592 US (Maryland) ➡ 312-626-6799 US (Chicago) ➡ 669-900-6833 US (California)

Meeting ID: 967 2812 9644 Passcode: 253540


About the Washington DC Archangels The Washington DC Archangels began as a collaborating partner of Ventana Capital, Irvine CA and is now a Chapter of the Orange County Archangels (California) and Chicago ArchAngels.  Members include active, high-energy private investors and investment leaders that work almost exclusively with enterprises with exceptional growth potential in the global marketplace. Their investments span a wide range of funding levels and include most industries, but all focus on “best of the best” companies with a multiplicity of revenue streams. Members continuously seek out new companies with high growth potential from across the nation and the globe, and then assist selected companies to increase their investment potential and success. Members actively provide companies the resources needed to accelerate rapid growth and create attractive opportunities for acquisitions and IPOs. An advisory board guides the Washington DC Archangels. Board members are serial entrepreneurs (those with extensive experience in creating, building and exiting a business) or represent venture capital firms or local groups of angel investors. All have a broad-based national business network of investment partners and business development experts, and several actively work with investors in Europe, Asia and the Americas. Members’ net worth ranges from SEC accreditation to several hundred million dollars. Washington DC Archangels' membership is limited and invitation-only. For more information about Washington DC Archangels and Private Capital Network, contact Dan Loague at Thanks, Dan Loague President Washington DC Archangels Cell: 405-824-5549


  • 1 hour

    Meeting Agenda

Registration is Closed

Share This Event